Short answer
MYRIAD GENETICS INC (MYGN) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $200M (up 2.3% year over year) with net income of −$34M.
Q1 2026 key financials · XBRL
- Revenue
- $200M
- +2.3% YoY
- Net income
- −$34M
- −34000.0% YoY
- Operating margin
- -15.3%
- Gross margin
- 68.7%
- EPS (diluted)
- −$0.36
Source: XBRL data from the MYRIAD GENETICS INC (MYGN) Q1 2026 10-Q on SEC EDGAR. USD.
MYRIAD GENETICS INC Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $200.4M, up $4.5M YoY from $195.9M
- Cost-of-revenue margin 68.7% vs 68.5% YoY
- Best segment Mental Health revenue $38.3M, up $7.3M YoY; worst Prenatal Health $41.9M, down $7.4M
- Cash $124.4M vs $149.6M; operating cash outflow $15.7M
- Headwinds: reimbursement limits, competition, borrowing costs; capital resources expected sufficient for 12 months
Risk Factors
- No risk-factors section provided in the submitted excerpt
- Credit agreement amendment dated January 5, 2026, identified in exhibits
- No equity repurchases during quarter ended March 31, 2026
- No director or executive Rule 10b5-1 trading-plan activity during quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MYRIAD GENETICS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.